Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Stock Short Interest Declines 87.1%

Posted by George Bondi on Oct 10th, 2026

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Get Free Report) was the recipient of a large drop in short interest in September. As of September 30th, there was short interest totaling 10,544 shares, a drop of 87.1% from the September 15th total of 81,947 shares. Based on an average daily trading volume, of 215,472 shares, the short-interest ratio is currently 0.0 days. Currently, 0.2% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on CMMB shares. Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 3rd. Weiss Ratings raised shares of Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Check Out Our Latest Stock Analysis on CMMB

Hedge Funds Weigh In On Chemomab Therapeutics

A hedge fund recently raised its stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC boosted its holdings in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Free Report) by 19.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,710 shares of the company’s stock after acquiring an additional 10,000 shares during the period. Kestra Private Wealth Services LLC owned 0.86% of Chemomab Therapeutics worth $97,000 at the end of the most recent reporting period. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Price Performance

Shares of Chemomab Therapeutics stock opened at $1.38 on Friday. The stock has a market capitalization of $10.01 million, a P/E ratio of -0.65 and a beta of 0.74. The business has a 50 day simple moving average of $2.13 and a two-hundred day simple moving average of $1.84. Chemomab Therapeutics has a 12 month low of $1.05 and a 12 month high of $3.50.

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last issued its quarterly earnings results on Thursday, August 20th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.12).

Chemomab Therapeutics Company Profile

(Get Free Report)

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is centered on CCL24, a chemokine believed to contribute to inflammation, fibrosis and tissue damage across several disease areas.

Chemomab’s lead product candidate is CM-101, a proprietary monoclonal antibody designed to block CCL24 activity. The therapy has been evaluated in clinical studies for conditions including primary sclerosing cholangitis, a progressive liver disease, and systemic sclerosis, an autoimmune disorder that can cause widespread fibrosis.